On December 18, 2020, Camurus AB, announced that the Swiss government approved sales of Buvidal, an extended-release injected version of buprenorphine. The approval was granted by Swissmedic, the national authorization and supervisory authority for drugs and medical products sold in Switzerland. Currently, about 20,000 Swiss residents are receiving pharmacological treatment for opioid dependence. The majority are receiving daily opioid agonist treatment. Buvidal is also approved for use in the European Union (EU) and in Australia since November 2018. In the EU Buvidal is available in Austria, Denmark, Finland, Germany, Norway, Sweden, and the United Kingdom. The medication is . . .
News Report |